目的:(1)评估肝脏动态对比增强(DCE)MRI过程中动脉输入功能(AIF)的质量;(2)量化肝细胞癌(HCC)和肝实质的灌注参数使用gadoxetate二钠与gadobenate二葡甲胺(Gd-BOPTA)在不同人群中进行DCE-MRI对比后的前3分钟。
方法:在这项前瞻性研究中,我们评估了66例接受DCE-MRI的83例HCC患者,使用gadoxetate二钠(第1组,n=28)或Gd-BOPTA(第2组,n=38)。评估了AIF的定性和定量特征。在肿瘤和肝实质中提取灌注参数(基于最初的3分钟后对比),包括无模型参数(峰值时间增强(TTP),冲洗时间)和建模参数(动脉流量(Fa),门静脉血流(Fp),总流量(Ft),动脉分数,平均运输时间(MTT),分配量(DV))。此外,测量病变与肝脏的对比比(LLCR)。采用Fisher精确检验和Mann-WhitneyU检验对两组进行比较。
结果:AIF质量,2组之间的HCC模型和无模型灌注参数相似(p=0.054-0.932).与第2组相比,第1组肝实质血流较低,肝脏增强发生较晚(Fp,p=0.002;Ft,p=0.001;TTP,MTT,所有p<0.001),而肿瘤LLCR没有显着差异(最大。呈阳性的LLCR,p=0.230;最大值。负LLCR,p=0.317)。
结论:与Gd-BOPTA相比,Gadoxetate二钠在动态阶段提供了可比的AIF质量和HCC灌注参数。尽管gadoxetate二钠的肝脏增强延迟和减少,LLCR在对比剂之间是等效的,表明相似的肿瘤显著性。
结论:•动脉输入功能质量,建模,在注射后的前3分钟内接受gadoxetate二钠或gadobenate二甲葡胺的患者中,在肝细胞癌中测量的无模型动态参数相似。•Gadoxetate二钠和Gadobenate二甲胺在HCC患者的动态阶段显示出相似的病变与肝脏的对比比。•与gadobenatedimeglumine相比,gadoxetatedidididium具有较低的门静脉和较低的总肝流量以及较长的肝平均运输时间和达到峰值的时间。
OBJECTIVE: (1) To assess the quality of the arterial input function (AIF) during dynamic contrast-enhanced (DCE) MRI of the liver and (2) to quantify perfusion parameters of hepatocellular carcinoma (HCC) and liver parenchyma during the first 3 min post-contrast injection with DCE-MRI using
gadoxetate disodium compared to gadobenate dimeglumine (Gd-BOPTA) in different patient populations.
METHODS: In this prospective study, we evaluated 66 patients with 83 HCCs who underwent DCE-MRI, using
gadoxetate disodium (group 1, n = 28) or Gd-BOPTA (group 2, n = 38). AIF qualitative and quantitative features were assessed. Perfusion parameters (based on the initial 3 min post-contrast) were extracted in tumours and liver parenchyma, including model-free parameters (time-to-peak enhancement (TTP), time-to-washout) and modelled parameters (arterial flow (Fa), portal venous flow (Fp), total flow (Ft), arterial fraction, mean transit time (MTT), distribution volume (DV)). In addition, lesion-to-liver contrast ratios (LLCRs) were measured. Fisher\'s exact tests and Mann-Whitney U tests were used to compare the two groups.
RESULTS: AIF quality, modelled and model-free perfusion parameters in HCC were similar between the 2 groups (p = 0.054-0.932). Liver parenchymal flow was lower and liver enhancement occurred later in group 1 vs group 2 (Fp, p = 0.002; Ft, p = 0.001; TTP, MTT, all p < 0.001), while there were no significant differences in tumour LLCR (max. positive LLCR, p = 0.230; max. negative LLCR, p = 0.317).
CONCLUSIONS: Gadoxetate disodium provides comparable AIF quality and HCC perfusion parameters compared to Gd-BOPTA during dynamic phases. Despite delayed and decreased liver enhancement with
gadoxetate disodium, LLCRs were equivalent between contrast agents, indicating similar tumour conspicuity.
CONCLUSIONS: • Arterial input function quality, modelled, and model-free dynamic parameters measured in hepatocellular carcinoma are similar in patients receiving gadoxetate disodium or gadobenate dimeglumine during the first 3 min post injection. •
Gadoxetate disodium and gadobenate dimeglumine show similar lesion-to-liver contrast ratios during dynamic phases in patients with HCC. • There is lower portal and lower total hepatic flow and longer hepatic mean transit time and time-to-peak with gadoxetate disodium compared to gadobenate dimeglumine.